Probability of receiving a high cumulative radiation dose and primary clinical indication of CT examinations: a 5-year observational cohort study

Cécile R L P N Jeukens, Hub Boere, Bart A J M Wagemans, Patty J Nelemans, Estelle C Nijssen, Rebecca Smith-Bindman, Joachim E Wildberger, Anna M Sailer

ABSTRACT

Objective High radiation exposure is a concern because of the association with cancer. The objective was to determine the probability of receiving a high radiation dose from CT (from one or more examinations within a 5-year period) and to assess the clinical context by evaluating clinical indications in the high-dose patient group.

Design Observational cohort study. Effective radiation dose received from one or more CT examinations within a predefined 5-year calendar period was assessed for each patient.

Setting Hospital setting.

Participants All patients undergoing a diagnostic CT examination between July 2013 and July 2018 at the Maastricht University Medical Center.

Primary and secondary outcome measures The primary outcome was the probability of receiving a high effective dose, defined as ≥100 mSv, from one or more CT examinations within 5 years as derived from a time-to-event analysis. Secondary outcomes were the clinical indication for the initial scan of patients receiving a high effective dose.

Results 100 672 CT examinations were performed among 49 978 patients including 482 (1%) who received a high radiation dose. The estimated probability of a high effective dose from a single examination is low (0.002% (95% CI 0.00% to 0.01%)). The 4.5-year probability of receiving a high cumulative effective dose was 1.9% (95% CI 1.6% to 2.2%) for women and 1.5% (95% CI 1.3% to 1.7%) for men. The probability was highest in age categories between 51 and 74 years. A total of 27 711 (5.5%) of patients underwent more than six CT examinations, and the probability of receiving a high effective dose was 16%. Among patients who received a high effective dose, most indications (80%) were oncology related.

Conclusions The probability of receiving a high radiation dose from CT examinations is small but not negligible. In the majority (80%) of high effective dose receiving patients, the indication for the initial scan was oncology related.

INTRODUCTION

In the 1970s, the development of CT paved the way for advanced diagnostic imaging. Improvements in technology over time have further increased the use of CT, including the introduction of CT perfusion studies, four-dimensional imaging, dual-energy CT imaging and high-speed CT-angiography whole body imaging. This increasing clinical value of CT imaging has resulted in an increase in the number of CT examinations over the last decade. As many diseases and health conditions persist over time, there is also a potential increase in the number of examinations a patient will undergo in his or her lifetime due to monitoring. A drawback of CT imaging is the use of ionising radiation, which for high exposure levels may incur a risk of cancer from as early as 2–5 years following imaging.
The risk of cancer associated with radiation exposure levels similar to those used for medical imaging is conventionally assessed using the linear no-threshold model.\(^6\)\(^8\)\(^9\) In this model, even the smallest radiation exposure level is considered to pose a risk, as extensive epidemiological data suggest effective doses in the range of 10–50 mSv are carcinogenic.\(^6\)\(^10\) Conversely, there remain organisations that question the risks associated with these exposures. Some organisations, such as the Health Physics Society and the American Association of Physicists in Medicine,\(^11\)\(^12\) suggest that cancer risks are small or non-existent with exposure levels below 100 mSv. However, effective doses of 100 mSv and above are consistently considered carcinogenic, with numerous efforts made to reduce the number of individuals exposed to these high effective doses.

In an effort to reduce radiation doses and the associated risks, CT vendors have developed technical solutions including dose modulation and iterative reconstruction methods. As a result, dose reductions have been achieved for some procedures, such as routine chest or abdominal CT where a single phase is obtained. However, technical developments permitting faster scans and use of multi-phase studies have also led to imaging that results in higher effective doses. In actual practice, while effective dose reduction has been possible over time, it has often been relinquished in favour of higher effective doses that lead to improved image quality. Furthermore, patients are often imaged repeatedly over time and may be receiving a high cumulative effective dose from multiple CT examinations. There is paucity of information in European settings on the percentage of patients undergoing CT examinations who accumulate high effective doses from recurrent CT examinations and clinical settings in which patients are likely to receive such high effective dose.

On the topic of high effective dose prevalence or subsequent clinical settings for the exams, some answers can be found in literature,\(^13\)\(^14\)\(^15\)\(^16\)\(^17\)\(^18\) none of which originate from our country. Furthermore, the incidence range of patients receiving high cumulative effective doses as reported in literature is wide: from 0% to 15% depending on study design and follow-up period. For some oncology patients with shortened life expectancy, cumulative effective doses may be considered of less importance since low 5-year survival implies low risk of radiation-induced malignancies. However, a recent study by Rehani et al\(^9\) found that 14.3% of the group of patients that received high effective doses (≥100 mSv) for non-malignant diagnoses were relatively young (<40 years).

To fill the gap in clinical literature on the topic, this observational study was conducted to determine the probability of receiving a high cumulative effective dose (≥100 mSv) from one or more CT examinations and to assess the primary clinical indication for imaging of high effective dose-receiving patients.

### METHODS

All CT examinations (diagnostic and CT-guided interventions) performed at Maastricht University Medical Center between 1 July 2013 and 1 July 2018 were included, and follow-up was assessed through 31 December 2019. This centre is primarily a tertiary university hospital while also serving as a community hospital. State-of-the-art equipment, advanced protocolling and dose quality assurance are the standard.\(^20\)\(^21\)\(^22\) The CT scanners included in this study are given in table 1. Follow-up was enabled by a single identification number for each patient.

### Data collection

Radimetrics dose management software (Radimetrics Enterprise Platform, Bayer Healthcare, Berlin,
started at the date of the first CT examination within the 5-year inclusion period (between 1 July 2013 and 1 July 2018). For the primary analysis of probability of receiving a high effective dose, the follow-up ended on the date of which a high cumulative effective dose (≥100 mSv) was reached or observations were censored at the end of the inclusion period (1 July 2018). The number of CT examinations recorded was equal to the number of CT examinations received during the follow-up period. The estimates of probability of receiving a high effective dose were calculated including 95% CIs for the total population and for subgroups according to sex, age and number of CT examinations. Differences between groups were tested using the log rank test. All statistical analyses were performed using SPSS (IBM SPSS Statistics; V.25) and Stata (Survival Analysis, Statacorp, V.13). P<0.05 was considered statistically significant.

Effective dose calculation
Effective dose was used to quantify radiation dose for each examination. Effective dose is the sum of the organ doses multiplied by tissue weighting factors, which depend on radio sensitivity of each organ but not on age or sex. It is a useful measure as it reflects both the total amount of radiation emitted from the scanner and the future cancer risk associated with those exposures. Thus, the effective dose is a whole body surrogate measure related to the radiation detriment. The unit of effective dose is the sievert, which equals 1 joule per kg (1 Sv=1J/kg).

In diagnostic imaging, effective doses are usually in the millisievert (mSv) range.

Effective doses were calculated using the Monte Carlo-based module embedded in the dose management software. To accommodate for patient variations in length and weight, the module incorporates phantom models including 17 different sizes and three pregnant versions. After mapping the CT examination onto the phantom model most closely matching patient characteristics, the effective dose is calculated including incorporation of specific scanner settings. Exams with an effective dose of 100 mSv or greater were considered high dose. Patients who received a cumulative effective dose of 100 mSv or greater over the 5-years of the study were considered to have a high dose.

Statistical analysis
The primary analysis estimates the probability of receiving a high cumulative effective dose with a single exam or within the 5-year study period after the initial CT scan. All CT examinations performed on one patient were counted irrespective of indication or examination type. The cumulative effective dose, total observation period and number of CT examinations were calculated for each patient using a custom software script written in Python (Python 3.4.4, Python Software Foundation, www.python.org). Among patients who received a high cumulative radiation dose at any one time during the study period, the clinical indication for the first CT scan was determined. For these high-dose patients, electronic medical records were individually reviewed with respect to the primary indication for imaging during the follow-up period ending on 31 December 2019.

Nominal and categorical variables are reported as absolute numbers and percentages. Continuous variables are reported as a mean with SDs (if normally distributed), or as a median with IQRs or range (for skewed distributions). Time-to-event (Kaplan-Meier) analyses were performed to estimate the probability of having the event of interest: a high cumulative effective dose. Follow-up of a patient started at the date of the first CT examination within the
A total of 482 patients received a high effective dose during the study period. Median age was 63 years (range 20–89). The majority of these patients (52.9%) received 6–10 CT examinations during the study period. The median follow-up period of high-dose patients was 4.2 years (range 12 days–6.5 years).

Baseline characteristics and primary clinical indications for imaging of patients receiving high effective dose
Baseline characteristics of high-dose patients are given in table 3. A total of 482 patients received a high effective dose during the study period. Median age was 63 years (range 20–89). The majority of these patients (52.9%) received 6–10 CT examinations during the study period. The median follow-up period of high-dose patients was 4.2 years (range 12 days–6.5 years).
Primary clinical indications for CT examinations in patients receiving high effective doses are given in Table 4. The majority of indications (80%) were related to evaluation or follow-up of a malignancy (wide variety of malignancies, predominantly breast cancer, urological and gastrointestinal malignancies), 8% to vascular disease (predominantly aortic aneurysm and dissection) and 8% to non-malignant abdominal disease (predominantly pancreatitis and complicated colitis).

DISCUSSION

This study included 100,672 CT examinations performed among 49,978 patients at a single tertiary referral centre within a 5-year calendar period. The probability of receiving a high effective dose (≥100 mSv) in a single CT exam was low (0.002% (95% CI 0.00% to 0.01%)). Nearly 40% of patients received multiple CT examinations, and the probability of receiving a high cumulative effective dose after 4.5 years was 1.9% for women and 1.5% for men. The probability of receiving a high effective dose from one to two CT examinations was 0.01% versus 16% from 6 to 10 CT examinations and 32% from ≥11 CT examinations.

Four hundred and eighty-two patients were identified as receiving a high cumulative effective dose, with a median age of 63 years (range 20–89). More than half of these patients underwent 6–10 CT examinations within the study period. As could be expected, almost all high-dose receiving patients underwent more than one CT examination. This is in line with a recent study25 where of a cohort of 8,952 patients receiving a high effective dose (≥100 mSv), only 33 received this in a single day or single procedure, which were all CT-guided interventions. Eighty per cent of the CT examination referrals for high-dose patients were oncology related. The latter is similar to findings reported in the literature.13–14 Although Rehani et al19 found 90% oncology-related referrals. At the centre of the current study, continuous effort is undertaken to optimise dose and image quality.20 22 23 While radiation doses at this centre are similar to those in Switzerland and Germany, they were found to be lower than radiation doses in the USA.21

These findings support tracking radiation dose on an individual level. Of course, every exam involving ionising radiation should be properly justified. Patient radiation tracking might hypothetically lead to increased dose awareness among radiologists and referring physicians. In a time where use of CT imaging continues to increase, awareness of the cumulative radiation exposure and the accompanying potential health risk, in particular for younger patients, may lead to more careful and deliberate consideration and justified use of CT examinations.

In the current study, radiation exposure was quantified by calculating the effective dose using a Monte Carlo-based module embedded in the dose management software. The effective dose was introduced by the International Commission on Radiological Protection as a measure for exposure to moderate and low levels of radiation.8 Effective dose can be related to health detriment but was not primarily intended to monitor individual risks. For risk–benefit assessment, the recommended method is to estimate the absorbed organ doses.8

Previous studies have reported percentages of patients receiving high cumulative radiation doses due to diagnostic CT imaging.13–17 However, reported results are difficult to compare with the current study due to differences in study design, population, follow-up and effective dose estimation methods (where either typical effective doses per CT examination13–15 or estimated effective doses16 17 26 were used). Also, a recent study by Rehani and Hauptman18 demonstrated up to a sixfold variation between countries in the estimated number of patients receiving high cumulative effective doses relative to the population of a country. Two population-based studies14 15
Figure 3  Kaplan-Meier curves that visualise the probability of receiving a cumulative effective dose of ≥100 mSv over time by (A) sex, (B) age category and (C) number of CT examinations within the study period. The follow-up time starts at the first CT examination.
used well-defined and large study populations living in specific areas of Spain (224,751 people) and the USA (54,447 adults). They reported analyses of the subgroups of inhabitants undergoing at least one CT examination in the study period. Reported estimates of the percentage of patients receiving a cumulative effective dose >100 mSv were 8.2% for a 12-year period in Spain and 1.9% for a 10-year period in the USA. The authors of the latter study indicate that they likely underestimated cumulative effective doses and percentages because average effective dose estimates per CT examination were taken. This does not account for higher BMI patients receiving higher effective doses. Conversely, the Spanish study is likely an overestimation as exposure was extrapolated, assuming the same exposure rate for patients that could not be followed for 12 years.

A few hospital-based studies report percentages of patients reaching a cumulative effective dose ≥100 mSv in patients referred for a CT examination. The highest percentage was reported by Sodickson et al in a cohort of 31,462 patients undergoing CT in a tertiary academic medical centre in the USA. Evaluation of all recorded CT exams over 22 years leading up to 2007 showed that 15% of patients received an effective dose ≥100 mSv. The percentage of patients receiving more than five CT examinations in this study is high (33%/22 years), which may explain the relatively high incidence of high-dose patients found. In a study by Rehani et al in patients from four centres (three in USA and one in Central Europe), the percentage of patients receiving a high effective dose ranged from 0.64% to 3.4% (average 1.3%) for a follow-up duration of 1–5 years. A survey yielding data from 20 countries reported percentages ranging from 0.0% to 5.0% with a follow-up duration ranging from 0.4 to 6.1 years. None of these hospital-based studies performed time-to-event (survival) analyses to account for differences in varying follow-up periods between patients, which might have led to bias.

A strength of the current study is that effective doses were calculated for each CT examination separately using a Monte Carlo-based module. This is in line with previous research and has the advantage of incorporating scanner-specific settings such as scan range rather than using generic literature-based effective dose values. Another strength of the current study is the treatment of patients with malignant disease, non-malignant disease, vascular disease, high energy trauma, and other conditions separately.

### Table 3 Baseline characteristics of high-dose patients (n=482)

| Category                              | No. (%) |
|---------------------------------------|---------|
| **Sex**                               |         |
| Women                                 | 256 (53.1) |
| Men                                   | 226 (46.9) |
| **Age (years)**                       |         |
| <18                                   | 0 (0.0) |
| 18–50                                 | 88 (18.3) |
| 51–64                                 | 194 (40.2) |
| 65–74                                 | 154 (32.0) |
| ≥75                                   | 46 (9.5) |
| **Number of CT examinations**         |         |
| 1–2                                   | 2 (0.4) |
| 3                                     | 6 (1.2) |
| 4                                     | 19 (3.9) |
| 5                                     | 29 (6.0) |
| 6–10                                  | 255 (52.9) |
| ≥11                                   | 171 (35.5) |

### Table 4 Clinical indication for imaging in high-dose patients (n=482)

| Category                              | Number of patients |
|---------------------------------------|--------------------|
| Malignancy                            | n=384 (79.7%)      |
| Breast cancer                         | 75                 |
| Urologic malignancy                   | 63                 |
| Colon carcinoma                       | 53                 |
| Rectum carcinoma                      | 29                 |
| Melanoma                              | 28                 |
| Pancreatic carcinoma                  | 24                 |
| Lung cancer                           | 19                 |
| Gynaecological malignancy             | 13                 |
| Hepatocellular carcinoma              | 14                 |
| Lymphoma                              | 13                 |
| Sarcoma                               | 11                 |
| Cholangio-carcinoma                   | 11                 |
| Testis malignancy                     | 10                 |
| Neuroendocrine tumour                 | 7                  |
| Head and neck tumour                  | 7                  |
| Gastrointestinal stromal tumour       | 4                  |
| Other: unknown primary                | 3                  |
| Non-malignant abdominal disease       | n=39 (8.1%)        |
| Pancreatitis                          | 28                 |
| Coilitis                              | 5                  |
| Kidney stones                         | 4                  |
| Liver lesion differentiation           | 2                  |
| Vascular disease                      | n=37 (7.7%)        |
| Aortic dissection                     | 16                 |
| Aortic aneurysm                       | 11                 |
| Other peripheral artery disease, vasculitis, heart valve pathology and acute bleeding | 9 |
| High energy trauma                    | n=9 (1.9%)         |
| Other                                  | n=13 (2.7%)        |
| Failed surgery                        | 9                  |
| Interstitial lung disease             | 4                  |
Kaplan-Meier analysis, which accounts for differences in follow-up periods between patients and provides a graph that visualises the increase in probability of receiving a high effective dose over time. Finally, the current paper adds information on the European context to the mainly US-centric information in current literature. Studies by Smith-Bindman et al show that effective doses at US sites are generally higher than those at European sites.

There are some limitations to our study. First, the analysis on cumulative effective dose was restricted to CT examinations that were performed at a single centre, which limits the ability to generalise. Maastricht University Medical Center serves as community hospital and a tertiary medical centre. The probability of receiving a high cumulative effective dose for patients who are referred to a tertiary centre will strongly depend on efforts undertaken to optimise the use of state-of-the-art CT scanners with respect to dose and image quality. CT examinations performed at other centres were not included in the cumulative effective dose analysis, nor was radiation exposure due to other sources such as conventional X-ray, fluoroscopy and nuclear medicine. As a result, cumulative effective doses will tend to underestimate. A potential solution for this matter requires a unique registration of patients over time in a broad perspective. Dose-related data can be tracked based on a unique personal number like the BSN in the Netherlands. This will require political support on that matter on a national or even a European level. Second, a recent study has shown that the absorption of contrast medium can considerably increase the absorbed dose in contrast-uptaking organs. The Monte Carlo-based module embedded in the dose management software used to estimate the effective dose in the current study does not incorporate this effect and may underestimate effective dose in contrast to media CT examinations. Third, the time-to-event analysis could only partially account for differences in follow-up period between patients. In the primary analysis, censoring the observations of patients who died or were referred to another hospital before the end of the inclusion period was not possible, because this information was not available. As a result, the numbers at risk during follow-up are overestimated and the probability of receiving a high cumulative effective dose may have been underestimated. The aforementioned limitations result in underestimation of cumulative effective dose, and therefore results must be interpreted as being minimum probabilities, further underscoring the necessity of tracking radiation dose.

CONCLUSIONS
The probability of receiving a high cumulative effective dose ≥100 mSv from CT examinations is small but not negligible and increases linearly with time. In the majority (80%) of high-dose-receiving patients the indication for the initial CT scan was oncology related. These findings advocate the need for patient dose tracking to gain insight into individual cumulative radiation exposure and to increase awareness of the radiation exposure among radiologists and referring physicians.

REFERENCES
1 Liguori C, Fraumenfelder G, Massaroni C. Emerging clinical applications of computed tomography. Med Devices 2015:8:265–78.
2 Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007;357:2277–84.
3 Mettler FA, Bhargava M, Faulkner K, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology 2009;253:520–31.
4 Hricak H, Brenner DJ, Adelstein SJ, et al. Managing radiation use in medical imaging: a multifaceted challenge. Radiology 2011;258:889–905.
5 Smith-Bindman R, Miglioretti DL, Johnson E, et al. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996–2010. JAMA 2012;307:2400–9.
6 Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Board of radiation effects research division on earth and life sciences national Research Council of the National academies. Washington, DC: The National Academies Press, 2006.
7 United Nations Scientific Committee on the Effects of Atomic Radiation. Sources, effects and risks of ionizing radiation Annex F radiation carcinogenesis in man, 1988.
CT exams: assessment of patients with non-malignant diseases, reasons for imaging and imaging appropriateness. *Eur Radiol* 2020;30:1839–46.

20 Boere H, Eijisvoogel NG, Sailer AM, et al. Implementation of size-dependent local diagnostic reference levels for CT angiography. *AJR Am J Roentgenol* 2018;210:W226–33.

21 Smith-Bindman R, Wang Y, Chu P, et al. International variation in radiation dose for computed tomography examinations: prospective cohort study. *BMJ* 2019;364:k4931.

22 Hendriks BMF, Schnerr RS, Milanesi G, et al. Computed tomography pulmonary angiography during pregnancy: radiation dose of commonly used protocols and the effect of scan length optimization. *Korean J Radiol* 2019;20:313–22.

23 Smith-Bindman R, Chu P, Wang Y, et al. Comparison of the effectiveness of single-component and multicomponent interventions for reducing radiation doses in patients undergoing computed tomography: a randomized clinical trial. *JAMA Intern Med* 2020;180:666–75.

24 Bayer HealthCare Medical Care. Radiation dose calculation in Radimetrics™ enterprise platform by Bayer. white paper RAD-INF-13-05988 Bayer healthcare, 2014.

25 Arellano RS, Yang K, Rehani MM. Analysis of patients receiving \( \geq 100 \text{ mSv} \) during a computed tomography intervention. *Eur Radiol* 2020. doi:10.1007/s00330-020-07458-5. [Epub ahead of print: 12 Nov 2020].

26 Martin CJ, Harrison JD, Rehani MM. Effective dose from radiation exposure in medicine: past, present, and future. *Phys Med* 2020;79:87–92.

27 Singh R, Mukhopadhyay K. Survival analysis in clinical trials: basics and must know areas. *Perspect Clin Res* 2011;2:145–8.

28 Zee J, Xie SX. The Kaplan-Meier method for estimating and comparing proportions in a randomized controlled trial with Dropouts. *Biosstat Epidemiol* 2018;2:23–33.

29 Persinakis K, Tzidakis A, Spanakis K, et al. The effect of iodine uptake on radiation dose absorbed by patient tissues in contrast enhanced CT imaging: implications for CT dosimetry. *Eur Radiol* 2018;28:151–8.